Abbott Prevails In $219M Whistleblower FCA Trial
A Texas federal jury on Thursday cleared Abbott Laboratories of accusations it improperly marketed bile duct stents for off-label uses, in a whistleblower False Claims Act case that had sought $219...To view the full article, register now.
Already a subscriber? Click here to view full article